Excellence is just the beginning.


French German Italian Portuguese Russian

Treatment Study for Patients with Relapsed/Refractory Multiple Myeloma

Clinical Trial Title: 
Phase II clinical trial of melflufen in combination with low dose dexamethasone in patients with relapsed/refractory multiple myeloma who are refractory to pomalidomide and/or daratumumab.
Clinical Trial Protocol ID: 
Clinical Trial Investigator Name: 
Agne Paner, MD
Clinical Trial Protocol Description: 

The goal of the trial is to assess efficacy and safety of melflufen in combination therapy in patients with relapsed/refractory multiple myeloma who are refractory to pomalidomie and/or daratumumab and to collect data.

Clinical Trial Eligibility Criteria: 

In order to participate you must meet the following criteria:

  • Have a prior diagnosis of multiple myeloma with documented disease progression in need of treatment at time of screening.
  • Have a minimum of 2 prior lines of therapy, including an IMiD and a PI, and is refractory to pomalidomide and/or daratumumab. (Refractory status includes patients who relapse while on therapy or within 60 days of last dose of pomalidomide and/or daratumumab in any line, regardless of response.)

You will be excluded from the study if any of the following criteria apply to you:

  • Have any medical conditions that, in the investigator’s opinion, would impose excessive risk to the patient or would adversely affect his/her participating in this study. Examples of such conditions are: a significant history of cardiovascular disease (e.g., myocardial infarction, significant conduction system abnormalities, uncontrolled hypertension, ≥ grade 3 thromboembolic event in the last 6 months).
  • Have evidence of mucosal or internal bleeding and/or is platelet transfusion refractory (i.e. platelet count fails to increase by > 10,000 cells/mm3 after a transfusion of an appropriate dose of platelets).
  • Have a known active infection requiring parenteral or oral anti-infective treatment within 14 days of initiation of treatment.

This is a partial list of elgibility requirements.

Clinical Trial Area: 
Blood Disorders and Hematologic Cancers
Contact Phone: 
(312) 942-4685
Contact Name: 
Christine Deskovich RN, BSN, OCN